Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo-HSCT were randomized on Day 3 Post-Infusion into low-dose (2.5 mg/day), high-dose (5 mg/day) hetrombopag groups, or a control group receiving thrombopoietin (300 U/kg/day). Endpoints included platelet/neutrophil engraftment time, PGF incidence, transfusion needs, and safety. Among 212 analyzed patients, platelet engraftment was faster in hetrombopag groups (median 13 days) versus controls (15 days; p = 0.001), with no dose-dependent difference (p = 0.821). Neutrophil engraftment was also accelerated (13 vs. 15 days; p = 0.002). PGF incidence was lower in hetrombopag groups (5.04%) versus controls (13.7%; p = 0.042). The experimental group required fewer platelet transfusions (p = 0.021), had reduced gastrointestinal bleeding, and lower costs. Secondary platelet recovery failure showed no intergroup differences. Hetrombopag safely accelerates platelet and neutrophil engraftment, reduces PGF risk, and decreases transfusion dependency post-allo-HSCT. Low-dose hetrombopag demonstrated efficacy equivalent to high-dose, offering a cost-effective strategy to improve transplant outcomes. Trial Registration: ChiCTR2200057764.
Keywords: GVHD; TPO‐RA; allo‐HSCT; hetrombopag; platelet engraftment.
© 2025 Wiley Periodicals LLC.